about
Tumor microenvironment complexity: emerging roles in cancer therapy.Osteopontin shapes immunosuppression in the metastatic niche.SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.Triggering CD40 on endothelial cells contributes to tumor growthGenetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stromaMatricellular proteins at the crossroad of inflammation and cancer.Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis.The bone marrow stroma in hematological neoplasms--a guilty bystander.Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.The good and bad of targeting cancer-associated extracellular matrix.RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B.Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer.Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments.Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.The ins and outs of osteopontin.SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.Microenvironment-centred dynamics in aggressive B-cell lymphomas.Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis.Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies.Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma.Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity.Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis.Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice.Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth.ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities.Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meetingThe matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responsesThe P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironmentBone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphomaImmune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer
P50
Q30419311-17667B5B-9F53-4403-8237-3C4A0BAF71F5Q34663294-617CED22-5FBC-4957-9B75-0702C1BBFD5EQ35679638-9A07D616-7824-4424-9C11-1A23CD3EB9D0Q36228064-492F53B1-A385-4FC5-B6C8-C066D5B6DCA3Q36782301-0F293D97-5DAB-4252-A612-F58D04879484Q37106218-965A64EC-C3C1-4759-B913-C87B2C161747Q37159990-54EDB0D4-C510-452E-A523-4DB8D560C13DQ37357090-787AA8AC-DB77-4B88-AE86-B32F095A4F2AQ37729913-D549E4F3-316E-4B53-99F0-3A6FB2563E8FQ37859253-6792C777-0AF2-481F-8214-E0ADB5C57EB2Q38327926-EDB32EBE-5662-4159-A584-507E4C319CBEQ38666873-187BE8C9-6ABB-4996-A86B-99EDB236688EQ38844181-F297F4D3-C4D1-4DCE-A866-601CD48ED71AQ38895904-B2ACFDC7-140A-4AB3-9069-BFF41999E4BEQ39114095-755520D6-D5ED-4778-B574-11F1DE910A1BQ39304713-1158A83E-5C2D-4E64-A99F-74102319E85BQ39478858-F909ADAD-7F14-418B-9D46-F19FFF3C4E0EQ39833021-62396E64-D519-4941-A10E-A8DCD3709C74Q41348331-FF71E4E5-6E92-4629-A0D7-859593B1AD35Q41570171-5D890783-826E-4F08-BDB3-016C3B74B209Q42477969-192414FC-A18B-4B7F-ABB0-0B05130E0AFEQ42745386-4EC9048E-D044-4893-8F32-1074F45E9F03Q43532771-81832461-9069-4193-8DB2-9255C15509B5Q44986451-DFF920ED-BD3F-4466-81DA-D806D94BB143Q45881105-298F62A8-0645-4C4F-9C0C-656A14F72AB8Q45885451-2D300DD2-4891-4BE4-AE86-2497C684BED8Q46695757-F915FB8C-3043-4008-BE51-4D827D21D4E2Q47194065-7D9B9E27-B79A-4351-81CD-478DF1CCB60EQ47807992-17FF4F65-C925-447F-8D85-5F84CD218CB1Q47976582-891FDEFA-8730-4928-B60F-60922226943EQ50042198-FE6587F7-6676-45B0-9757-2D2F15C66D61Q50985206-9CF631FE-14A4-4474-AABA-F82A91B3E2A9Q51452570-89E8F636-522E-40DF-B141-F73C61A6BC74Q54328655-3251118F-AD3A-4C8A-BBD2-64857C7C4599Q58590757-B2AAC3AB-8B46-470D-B62B-06BC079D1A77Q59417915-00444EF5-48DA-4A1B-B0CA-F3D95D9BA166Q62590783-87D0D5FA-9344-415D-BC00-F03C0FDFC547Q62597252-C223A6A6-FE89-49E3-896A-3357EB3DBDB8Q64967509-0ADF8A1E-C897-4031-B125-A346E5D465C8Q88012879-0C10AEFF-919B-4B75-8146-83ABC25C4C93
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sabina Sangaletti
@ast
Sabina Sangaletti
@en
Sabina Sangaletti
@es
Sabina Sangaletti
@nl
Sabina Sangaletti
@sl
type
label
Sabina Sangaletti
@ast
Sabina Sangaletti
@en
Sabina Sangaletti
@es
Sabina Sangaletti
@nl
Sabina Sangaletti
@sl
prefLabel
Sabina Sangaletti
@ast
Sabina Sangaletti
@en
Sabina Sangaletti
@es
Sabina Sangaletti
@nl
Sabina Sangaletti
@sl
P1053
C-4495-2017
P106
P1153
6506304282
P21
P31
P3829
P496
0000-0001-7047-287X